'In this article, we discuss the potential role of N-of-1 trials in cancer drug development in the era of personalized cancer medicine. We also elaborate on a suggested modified design for N-of-1 trials able to overcome limitations and make this concept more applicable to clinical oncology.'
https://aacrjournals.org/cancerdiscovery/article/13/6/1301/726949/N-of-1-Trials-in-Cancer-Drug-Development
Thiago Carvalho /
npub1xa…czham
2024-07-15 09:55:43
Author Public Key
npub1xakev87fgm9edqu6f5jhszwunekjxl3dpnq4sxvm3nzu2ace8xnqyczhamPublished at
2024-07-15 09:55:43Event JSON
{
"id": "c5e9b1b070516f46c4a3a4dd984459bf4845019d9d780101cce5263631532883",
"pubkey": "376d961fc946cb96839a4d257809dc9e6d237e2d0cc158199b8cc5c5771939a6",
"created_at": 1721037343,
"kind": 1,
"tags": [
[
"proxy",
"https://qoto.org/users/cyrilpedia/statuses/112789903305141291",
"activitypub"
]
],
"content": "'In this article, we discuss the potential role of N-of-1 trials in cancer drug development in the era of personalized cancer medicine. We also elaborate on a suggested modified design for N-of-1 trials able to overcome limitations and make this concept more applicable to clinical oncology.'\n\nhttps://aacrjournals.org/cancerdiscovery/article/13/6/1301/726949/N-of-1-Trials-in-Cancer-Drug-Development",
"sig": "13470b12840d266392888c3c86c9fe4e40d41486244b8bd03e7221f864f6de1d605f74b053af2a36444f593989019f9b6b0934875ebcb612bff59c1bfbdb7a58"
}